Business Description
Nicox SA
ISIN : FR0013018124
Share Class Description:
FRA:NXOA: Share from reverse splitDescription
Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Its lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Its first product, VYZULTA in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE in allergic conjunctivitis, licensed in multiple geographies.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.32 | |||||
| Equity-to-Asset | 0.4 | |||||
| Debt-to-Equity | 1.19 | |||||
| Debt-to-EBITDA | -3.22 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -14.43 | |||||
| Beneish M-Score | -4.25 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -32.3 | |||||
| 3-Year EBITDA Growth Rate | 8 | |||||
| 3-Year EPS without NRI Growth Rate | 8 | |||||
| 3-Year Book Growth Rate | -46 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 43.39 | |||||
| 9-Day RSI | 47.03 | |||||
| 14-Day RSI | 48.83 | |||||
| 3-1 Month Momentum % | 67.59 | |||||
| 6-1 Month Momentum % | 108.85 | |||||
| 12-1 Month Momentum % | -31.7 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.46 | |||||
| Quick Ratio | 1.46 | |||||
| Cash Ratio | 0.82 | |||||
| Days Sales Outstanding | 101.76 | |||||
| Days Payable | 53.16 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10.4 | |||||
| Shareholder Yield % | -3.71 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -74.3 | |||||
| Operating Margin % | -93.44 | |||||
| Net Margin % | -126.37 | |||||
| FCF Margin % | -83.81 | |||||
| ROE % | -43.58 | |||||
| ROA % | -20.5 | |||||
| ROIC % | -18.78 | |||||
| 3-Year ROIIC % | 16.17 | |||||
| ROC (Joel Greenblatt) % | -4540 | |||||
| ROCE % | -20.36 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.75 | |||||
| PB Ratio | 0.97 | |||||
| Price-to-Tangible-Book | 0.97 | |||||
| EV-to-EBIT | -3.41 | |||||
| EV-to-EBITDA | -5.06 | |||||
| EV-to-Forward-EBITDA | -1.24 | |||||
| EV-to-Revenue | 3.72 | |||||
| EV-to-Forward-Revenue | 13.39 | |||||
| EV-to-FCF | -4.44 | |||||
| Price-to-GF-Value | 0.38 | |||||
| Earnings Yield (Greenblatt) % | -29.33 | |||||
| FCF Yield % | -39.65 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nicox SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 9.992 | ||
| EPS (TTM) (€) | -0.235 | ||
| Beta | 1.15 | ||
| 3-Year Sharpe Ratio | -0.43 | ||
| 3-Year Sortino Ratio | -0.77 | ||
| Volatility % | 145.74 | ||
| 14-Day RSI | 48.83 | ||
| 14-Day ATR (€) | 0.025011 | ||
| 20-Day SMA (€) | 0.259575 | ||
| 12-1 Month Momentum % | -31.7 | ||
| 52-Week Range (€) | 0.102 - 0.44 | ||
| Shares Outstanding (Mil) | 69.01 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nicox SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nicox SA Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Nicox SA Frequently Asked Questions
What is Nicox SA(FRA:NXOA)'s stock price today?
The current price of FRA:NXOA is €0.26. The 52 week high of FRA:NXOA is €0.44 and 52 week low is €0.10.
When is next earnings date of Nicox SA(FRA:NXOA)?
The next earnings date of Nicox SA(FRA:NXOA) is 2025-05-31 Est..
Does Nicox SA(FRA:NXOA) pay dividends? If so, how much?
Nicox SA(FRA:NXOA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers